Key result
Alprenolol and propranolol were compared against placebo for treating angina pectoris, but the truncated abstract does not report the clinical efficacy or safety outcomes.
Key points are not available for this paper at this time.
Truncated reporting yields no efficacy or safety data for beta-blockers in angina; leaves open their comparative utility.
Twenty-six patients with typical angina pectoris were treated with alternating four-week courses of alprenolol 400 mg daily, propranolol i6o mg daily, and placebo for 12 months (standard dose regimen). Subsequently, 17 of the patients took part in a 6-month dose-response study in which the dose was increased by one and a
No takes yet. Share an insight, caveat, or question.
Heterington et al. (1973) studied this question. Alprenolol and propranolol were compared against placebo for treating angina pectoris, but the truncated abstract does not report the clinical efficacy or safety outcomes.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: